Diabetes: Vascular or Neurodegenerative
2008; Lippincott Williams & Wilkins; Volume: 40; Issue: 3_suppl_1 Linguagem: Alemão
10.1161/strokeaha.108.533075
ISSN1524-4628
Autores Tópico(s)Neurological Disease Mechanisms and Treatments
ResumoHomeStrokeVol. 40, No. 3_suppl_1Diabetes: Vascular or Neurodegenerative Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBDiabetes: Vascular or NeurodegenerativeAn Epidemiologic Perspective Lenore J. Launer, PhD Lenore J. LaunerLenore J. Launer From the Laboratory of Epidemiology, Demography and Biometry, National Institute on Aging, Bethesda, Md. Originally published8 Dec 2008https://doi.org/10.1161/STROKEAHA.108.533075Stroke. 2009;40:S53–S55Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: December 8, 2008: Previous Version 1 Type 2 diabetes and cognitive impairment are 2 of the most common chronic conditions found in persons 60 years and older. After that age, approximately 18% to 20% of older persons have diabetes,1 approximately 19% suffer from mild cognitive impairment in multiple domains,2 and approximately 6% of community-dwelling individuals have some dementia.3 The prevalence of mild cognitive impairment and dementia increases with age as does the prevalence of diabetes; there is also an alarming trend toward a younger age of diabetes onset.4 Several lines of investigation suggest a link among diabetes, cognitive impairment, and dementia, described briefly subsequently. Thus, the age-related trends in diabetes and cognitive disorders indicate a further increase in the number of persons with mild cognitive impairment and dementia, beyond the increase that is expected as the population ages.What Is the Evidence Linking Diabetes to Late-Age Cognitive Disorders?Clinical studies have shown impaired neuropsychological functioning in patients with diabetes.5 Compared with community-dwelling normoglycemic persons, those with diabetes have a higher prevalence of global cognitive impairment6 and a higher incidence of cognitive decline.7 Population-based studies have also shown that diabetes is a risk factor for Alzheimer disease (AD),8–11 the most common form of dementia.The association of diabetes to cognitive disorders may be moderated by a spectrum of factors that range from healthcare access to genetic susceptibility. For example, data from several studies suggest those with diabetes and who are apolipoprotein E ε4 allele (a genetic susceptibility risk factor for AD) carriers are at higher risk for a cognitive disorder than those with no diabetes and no ε4 allele, or either one alone.12–14 Wu15 showed in the SALSA study of Hispanics that characteristics of diabetes, including treatment and duration, were associated with global cognitive function: longer duration was associated with lower cognitive function and treatment with higher function. Additional modulation of risk may come from comorbidities of diabetes. For instance, between diabetes and hypertension has been reported to increase the risk for global atrophy16 and performing poorly on a test of visual memory.17The metabolic and hemodynamic profile of diabetes, including comorbidities such as hypertension, hyperinsulinemia, and obesity,18 modulates vascular health and neuronal survival through multiple mechanisms. Pathophysiological mechanisms that have been identified include inflammation, oxidative stress, energy imbalance, protein misfolding, glucocorticoid-mediated effects, and differences in gene expression.19–24 More recently, several endocrine proteins, angioneurins (ie, vascular endothelial growth factor) have been shown to modify both vascular health and neuronal survival.25 Finally, genetic findings may identify new pathways contributing to diabetes that may also contribute to cerebral disease.26In the context of rapidly increasing evidence that diabetes can have a critical role in disease causing mixed cerebral brain pathophysiology, type 2 diabetes cerebral disease is still largely considered to be large vessel infarction. It is notable from recent reviews27 that little is known about the prevalence and incidence of brain changes or the functional sequelae of small and microvascular cerebral disease in persons with diabetes. For instance, does microvascular disease, common in diabetes-related peripheral neuropathy, nephropathy, and retinopathy, extend to the brain?Integrated Community-Based Studies of Diabetes and the BrainDespite major gaps in our knowledge of the interaction of diabetes and cerebral disease, an increasing body of data suggest the hypothesis that diabetic pathologies lead to both the AD-type neurodegeneration as well as vascular damage, and it is this mix of these diseases that forms the anatomical basis for clinical and subclinical cognitive impairment in diabetes. To test this hypothesis, an integrated vertical approach is needed that is based on multiple measures of brain structure/function. The Honolulu Asia Aging Study (HAAS),9 the Age Gene/Environment Susceptibility–Reykjavik Study (AGES-Reykjavik Study),28 and the Memory in Diabetes (MIND)29 substudy embedded in the ACCORD trial30 provide the opportunity to take this approach.The HAAS began in 1991 as a continuation of the Honolulu Heart Program, a population-based longitudinal study of Japanese-American men born between 1900 and 1919 and living in Oahu, Hawaii, when the study began in 1965. Participants were seen at 3 midlife examinations (1965 to 1968, 1968 to 1970, 1971 to 1974) and at 4 examinations in late life (1991 to 1993, 1994 to 1996, 1997 to 1999; 2001 to 2002). Clinical measurements, demographic information, and medical information were collected at each examination. Starting in 1991, global cognitive function was measured in the total sample and cases of dementia ascertained. An autopsy study nested within the cohort was also started in 1991; an MRI substudy of 575 men was performed in 1995 to 1996.The AGES-Reykjavik Study is a population-based follow-up study of men and women born from 1907 to 1934. The cohort was established in 1967 by the Icelandic Heart Association; participants were examined up to 6 times. From 2002 to 2006, 5764 cohort members were re-examined as a part of the AGES-Reykjavik Study. All participants were administered a battery of cognitive tests of speed, memory, and working memory; and all eligible participants underwent a brain MRI. Retinal photographs, which provide a measure of microvessels, were also acquired.HAAS has provided valuable insights on the association of diabetes and related risk factors, high blood pressure and hyperinsulinemia, to clinical disease and brain pathology.31–34 In this cohort, diabetes is associated with both vascular disease, ie, infarcts, and neurodegenerative changes, ie, hippocampal atrophy, which are frequently seen in AD.35 Consistent with the findings on clinical AD, we found those with diabetes and an apolipoprotein E ε4 allele, compared with those with neither, had an increased risk for cerebral amyloid angiopathy, neuritic plaques, and neurofibrillary tangles, all common markers in AD.9To further address the question of microvascular disease in older persons with diabetes, we examined the association of cerebral microbleeds to retinal lesions in the AGES-Reykjavik Study. We found an increased risk for multiple microbleeds in the presence of arteriovenous nicking (2.47; 95% CI, 1.42 to 4.31) and retinal hemorrhages (2.28; 95% CI, 1.24 to 4.18). These associations were stronger in diabetic subjects compared with nondiabetic subjects, suggesting microvascular disease may extend to the brain of persons with diabetes.36These brain structure studies establish an association of diabetes to neurodegenerative and vascular brain pathology. Experimental data are needed to articulate mechanisms (ie, see 24). From an epidemiological perspective, longitudinal assessments of macro- and microstructural changes are needed to better understand the trajectory and functional consequences of diabetes-related cerebral disease.In addition to studying the possible physiological contribution of diabetes to late-age brain pathology, studies of diabetes disease management and cognitive disorders are needed.ACCORD MIND29,30 is a substudy embedded in the clinical trial ACCORD, which is designed to investigate the efficacy of intensive (to reduce HbA1C to <6.0%) versus standard treatment (to obtain HbA1c of 7% to 7.9%) of hyperglycemia to reduce cardiovascular events. MIND aims to test the effect on brain structure and function of intensive treatment compared with standard treatment. This comparison takes on new dimensions because the intensive glycemic arm of ACCORD was recently stopped for safety reasons.30 Analyses are in progress to understand the effect of treatment strategy on brain outcomes. In addition, several other important questions will be addressed such as how cognitive disorders influence an individual's ability to follow a disease management protocol and whether frequent hypoglycemia events contribute to cognitive dysfunction.In summary, data suggest, compared with nondiabetic individuals, those with diabetes have brain structural changes that reflect neuronal degeneration as well as vascular damage, and it is likely diabetes leads to microstructural changes not seen on standard MRI. Many factors modulate the strength of the association between diabetes and brain structure/function. Areas of interest to further investigate include pathophysiology of diabetes and the brain, genetic contributions to the associations of diabetes and brain, and the clinical and functional consequences of diabetes.Sources of FundingAGES-Reykjavik is supported by the National Institutes of Health contract N01-AG-12100, the National Institute on Aging Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). Components of the study were also supported by the National Eye Institute, the National Institute on Deafness and Other Communication Disorders, and the National Heart, Lung and Blood Institute. HAAS has been supported by the Intramural Research Program of the National Institutes of Health, the National Institute on Aging (grants U01 AG019349 and R01 AG0-17155 S1), and the National Heart, Lung, and Blood Institute (grant N01 HC05102).DisclosuresNone.FootnotesCorrespondence to Lenore J. Launer, MD, Laboratory of Epidemiology, Demography and Biometry, National Institute on Aging, Bethesda, MD 20892. E-mail [email protected] References 1 Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998; 21: 518–524.CrossrefMedlineGoogle Scholar2 Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003: 1385–1389.MedlineGoogle Scholar3 Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MMB, Copeland JRM, Dartigues J-F, Jagger C, Martinez-Lage J, Soininen H, Hofman A, for the Neurologic Diseases in the Elderly Research Group. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000; 54: S4–S9.CrossrefMedlineGoogle Scholar4 Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract. 2007; 76 (suppl 1): S3–12.CrossrefMedlineGoogle Scholar5 Coker L, Schumaker SA. Type 2 diabetes mellitus and cognition: an understudied issue in women's health. J Psychosom Res. 2003; 54: 129–139.CrossrefMedlineGoogle Scholar6 Kalmijn S, Feskens EJM, Launer LJ, Stijen T, Kromhout D. Glucose intolerance, hyperinsulemia, and cognitive function in a general population of elderly men. Diabetologica. 1995; 38: 1096–1102.CrossrefMedlineGoogle Scholar7 Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings SR. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med. 2000; 160: 174–180.CrossrefMedlineGoogle Scholar8 Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol. 1997; 145: 301–308.CrossrefMedlineGoogle Scholar9 Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002; 51: 1256–1262.CrossrefMedlineGoogle Scholar10 Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001; 154: 635–641.CrossrefMedlineGoogle Scholar11 Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology. 1999; 53: 1937–1942.CrossrefMedlineGoogle Scholar12 Haan MN, Shemanski L, Jagust WJ, Manolio T, Kuller L. The role of Apo E ε4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999; 281: 40–46.Google Scholar13 Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based sample of elderly men. Stroke. 1996; 27: 2230–2235.CrossrefMedlineGoogle Scholar14 Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol. 2008; 65: 89–93.MedlineGoogle Scholar15 Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol. 2003; 13: 369–376.CrossrefMedlineGoogle Scholar16 Schmidt R, Launer LJ, Nilsson LG, Pajak A, Sans S, Berger K, Breteler MM, De Ridder M, Dufouil C, Fuhrer R, Giampaoli S, Hofman A. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes. 2004; 53: 687–692.CrossrefMedlineGoogle Scholar17 Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H, Wolf PA. NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care. 1997; 20: 1388–1395.CrossrefMedlineGoogle Scholar18 Gustafson D. Adiposity indices and dementia. Lancet Neurol. 2006; 5: 713–720.CrossrefMedlineGoogle Scholar19 Klein JP, Waxman SG. The brain in diabetes: molecular changes in neurons and their implications for end-organ damage. Lancet Neurol. 2003; 2: 548–554.CrossrefMedlineGoogle Scholar20 Baumbach GL. Changes in the cerebral circulation in chronic hypertension. In: Bevan RD, Bevan JA, eds. The Human Brain Circulation. New Jersey: Humana Press; 1994: 421–431.Google Scholar21 Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol. 1998; 153: 1149–1155.CrossrefMedlineGoogle Scholar22 Hoyer S. Is sporadic Alzheimer's disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm. 1998; 105: 415–422.CrossrefMedlineGoogle Scholar23 Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004; 3: 169–178.CrossrefMedlineGoogle Scholar24 Stranahan AM, Lee K, Pistell PJ, Nelson CM, Readal N, Miller MG, Spangler EL, Ingram DK, Mattson MP. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci. 2008; 11: 309–317.CrossrefMedlineGoogle Scholar25 Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signaling defects in neurodegeneration. Nat Rev Neurosci. 2008; 9: 169–181.CrossrefMedlineGoogle Scholar26 Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007; 316: 1331–1336.CrossrefMedlineGoogle Scholar27 van Harten B, de Leeuw FE, Weinstein HC, Scheltens HC, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. Lancet Neurol. 2006; 11: 2539–2548.Google Scholar28 Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, Thorgeirsson G, Aspelund T, Garcia ME, Cotch MF, Hoffman HJ, Gudnason V. Age, Gene/Environment Susceptibility–Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol. 2007; 165: 1076–1087.CrossrefMedlineGoogle Scholar29 Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ; ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol. 2007; 99: 112i–122i.CrossrefMedlineGoogle Scholar30 Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545–2559.CrossrefMedlineGoogle Scholar31 Petrovitch H, White LR, Izmirlian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Neurobiol Aging. 2000; 21: 57–62.MedlineGoogle Scholar32 Havlik RJ, Foley DJ, Sayer B, Masaki K, White L, Launer LJ. Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu-Asia Aging Study. Stroke. 2002; 33: 26–30.CrossrefMedlineGoogle Scholar33 Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology. 2004; 63: 228–233.CrossrefMedlineGoogle Scholar34 Marlowe L, Peila R, Benke KS, Hardy J, White LR, Launer LJ, Myers A. Insulin-degrading enzyme haplotypes affect insulin levels but not dementia risk. Neurodegener Dis. 2006; 3: 320–326.CrossrefMedlineGoogle Scholar35 Korf-Pelgrim E, White LR, Scheltens PH, Launer LJ. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care. 2006; 29: 2268–2274.CrossrefMedlineGoogle Scholar36 Qiu C, Cotch MF, Sigurdsson S, Garcia M, Klein R, Jonasson F, Klein BE, Eiriksdottir G, Harris TB, van Buchem MA, Gudnason V, Launer LJ. Retinal and cerebral microvascular signs and diabetes: the Age, Gene/Environment Susceptibility–Reykjavik Study. Diabetes. 2008; 57: 1645–1650.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Kim B (2021) Differential Influence of Diabetes on Stroke Subtype Stroke Revisited: Diabetes in Stroke, 10.1007/978-981-16-5123-6_7, (69-79), . McNay E and Pearson-Leary J (2020) GluT4: A central player in hippocampal memory and brain insulin resistance, Experimental Neurology, 10.1016/j.expneurol.2019.113076, 323, (113076), Online publication date: 1-Jan-2020. Hansra G, Popov G, Banaczek P, Vogiatzis M, Jegathees T, Goldsbury C and Cullen K (2019) The neuritic plaque in Alzheimer's disease: perivascular degeneration of neuronal processes, Neurobiology of Aging, 10.1016/j.neurobiolaging.2019.06.009, 82, (88-101), Online publication date: 1-Oct-2019. Qiu C, Sigurdsson S, Zhang Q, Jonsdottir M, Kjartansson O, Eiriksdottir G, Garcia M, Harris T, van Buchem M, Gudnason V and Launer L (2014) Diabetes, markers of brain pathology and cognitive function, Annals of Neurology, 10.1002/ana.24063, 75:1, (138-146), Online publication date: 1-Jan-2014. Hugenschmidt C and Williamson J (2014) Solving the mystery of the diabetes–dementia connection: New clues — but far from "case closed", Journal of Diabetes and its Complications, 10.1016/j.jdiacomp.2013.09.012, 28:1, (8-9), Online publication date: 1-Jan-2014. Driscoll I, Espeland M and Yaffe K (2013) Cognitive Functioning in Aging Women Women and Health, 10.1016/B978-0-12-384978-6.00101-1, (1489-1502), . Fielding R, Gunstad J, Gustafson D, Heymsfield S, Kral J, Launer L, Penninger J, Phillips D, Scarmeas N and Kral J (2013) The paradox of overnutrition in aging and cognition, Annals of the New York Academy of Sciences, 10.1111/nyas.12138, 1287:1, (31-43), Online publication date: 1-May-2013. Prakash R, Somanath P, El-Remessy A, Kelly-Cobbs A, Stern J, Dore-Duffy P, Johnson M, Fagan S and Ergul A (2012) Enhanced Cerebral but Not Peripheral Angiogenesis in the Goto-Kakizaki Model of Type 2 Diabetes Involves VEGF and Peroxynitrite Signaling, Diabetes, 10.2337/db11-1528, 61:6, (1533-1542), Online publication date: 1-Jun-2012. Di Legge S and Hachinski V (2010) Vascular cognitive impairment (VCI): Progress towards knowledge and treatment, Dementia & Neuropsychologia, 10.1590/S1980-57642010DN40100002, 4:1, (4-13), Online publication date: 1-Mar-2010. Mortimer J, Borenstein A, Ding D, DeCarli C, Zhao Q, Copenhaver C, Guo Q, Chu S, Galasko D, Salmon D, Dai Q, Wu Y, Petersen R and Hong Z (2010) High normal fasting blood glucose is associated with dementia in Chinese elderly, Alzheimer's & Dementia, 10.1016/j.jalz.2010.03.017, 6:6, (440-447), Online publication date: 1-Nov-2010. Arboix A (2014) Stroke prognosis in diabetes mellitus: new insights but questions remain, Expert Review of Cardiovascular Therapy, 10.1586/erc.09.98, 7:10, (1181-1185), Online publication date: 1-Oct-2009. Goh D, Dong Y, Lee W, Koay W, Tay S, Soon D, Chen C, Brittain C, Lowe S, Wong B and Holscher C (2014) A Pilot Study to Examine the Correlation between Cognition and Blood Biomarkers in a Singapore Chinese Male Cohort with Type 2 Diabetes Mellitus, PLoS ONE, 10.1371/journal.pone.0096874, 9:5, (e96874) Launer L, Lewis C, Schreiner P, Sidney S, Battapady H, Jacobs D, Lim K, D'Esposito M, Zhang Q, Reis J, Davatzikos C, Bryan R and Ikram M (2015) Vascular Factors and Multiple Measures of Early Brain Health: CARDIA Brain MRI Study, PLOS ONE, 10.1371/journal.pone.0122138, 10:3, (e0122138) Kwasny M, Oleske D, Zamudio J, Diegidio R and Höglinger G (2021) Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy, Frontiers in Neurology, 10.3389/fneur.2021.637176, 12 Chen S, Meng F, Chen Z, Tomlinson B, Wesley J, Sun G, Whaley-Connell A, Sowers J, Cui J, Gu Z and St-Pierre Y (2015) Two-Dimensional Zymography Differentiates Gelatinase Isoforms in Stimulated Microglial Cells and in Brain Tissues of Acute Brain Injuries, PLOS ONE, 10.1371/journal.pone.0123852, 10:4, (e0123852) Mortby M, Janke A, Anstey K, Sachdev P, Cherbuin N and Paul F (2013) High "Normal" Blood Glucose Is Associated with Decreased Brain Volume and Cognitive Performance in the 60s: The PATH through Life Study, PLoS ONE, 10.1371/journal.pone.0073697, 8:9, (e73697) March 2009Vol 40, Issue 3_suppl_1 Advertisement Article InformationMetrics https://doi.org/10.1161/STROKEAHA.108.533075PMID: 19064803 Manuscript receivedJuly 30, 2008Originally publishedDecember 8, 2008 Keywordsdiabetesvascular dementiaPDF download Advertisement
Referência(s)